CROP’S Emerald Heights San Bernardino Cannabis Business Retail Application on Final Phase
Momentum Public Relations
Press Release: February 12, 2019
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has received confirmation that its San Bernardino retail cannabis business application has now advanced to stage four of the application review process.
As previously announced on July 5th 2018, CROP agreed to finance the purchase of real estate upon the granting of a California dispensary license. The proposed dispensaries will operate under the brand “Emerald Heights”.
CROP and its partners will attend a special mayor and city council meeting to make a three minute presentation followed by a question and answer session. Subject to a successful outcome, Emerald Heights will be licensed to open its San Bernardino retail location on the city’s busiest intersection next to the fairgrounds which has ample parking for customers.
CROP CEO, Michael Yorke, stated: “CROP has high expectations for Emerald Heights at this location. The team has done its market and location research very well and are now in the final phase of the application process in San Bernardino. We believe the community will enjoy the opportunity to share an elevated adult retail experience that the Emerald Heights brand will provide.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Phone: +1(604)-484-4206
Website: www.cropcorp.com
- Published in CROP Infrastructure, hemp, Marijuana, News Home
Mondias Announces an Amendment to its Stock Option Plan
Momentum Public Relations
Press Release: February 11, 2019
Mondias Natural Products Inc. (TSXV: NHP) (“Mondias” or the “Corporation”), a Corporation that specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets, announces that its Board of Directors has approved an amendment to its stock option plan to become effective upon approval by the shareholders of the Corporation at the Annual General Meeting of shareholders to be held later this year and upon receipt of final approval by the TSX Venture Exchange Inc. A copy of the proposed Stock Option Plan will be available from the Chief Executive Officer of the Corporation upon request and will be attached to the Information Circular to be filed on SEDAR, at www.sedar.com, for the upcoming Annual General Meeting of the shareholders.
The Corporation proposes to replace the fixed 20% stock option plan with a rolling 10% stock option plan. Under the rolling 10% stock option plan, the Corporation may grant options to acquire common shares of the Corporation equal to 10% of the issued and outstanding shares from time to time subject to the terms and conditions prescribed by the TSX Venture Exchange Inc. and applicable securities laws.
Currently outstanding options to purchase common shares of the Company granted prior to the amendment will continue to be exercisable and will be governed by and subject to the terms of the amended plan.
Based on the Company’s current issued and outstanding common share amount of 63,135,805, the amended rolling plan maximum is currently 6,313,581 common shares. Prior to the amendments to the plan, the fixed plan maximum was 400,408 common shares.
On January 22, 2019, the Board of Directors had approved the grant, subject to shareholder and regulatory approval, of incentive stock options under the amended 2019, 10% Rolling Stock Option Plan to the directors and officers of the Corporation for the purchase of a total of 2,550,000 shares in its capital. The options are exercisable before January 22, 2029, at the price of $0.235 per share (the closing price of the shares on January 21, 2019). The stock options vest over a 3-year period, with the first vesting period delayed until all regulatory and shareholder approvals are received.
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/11/c1683.html
Contact:
Jean Philippe Gravel, CEO, Telephone: 514-804-4569, Email : jpgravel@mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home
Cannara Biotech Shares to Begin Trading on the Frankfurt Exchange
Momentum Public Relations
Press Release: February 11, 2019
Cannara Biotech Inc. (“Cannara Biotech” or the “Company”) (CSE: LOVE) (FRA: 8CB), a vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced its common shares are listed for trading on the Frankfurt Stock Exchange under the trading symbol “8CB”. The Company’s common shares continue to be listed on the Canadian Securities Exchange under the trading symbol “LOVE”.
The Frankfurt Stock Exchange is the tenth largest stock exchange in the world by market capitalization and third largest in terms of volume. It is Germany’s largest stock exchange.
“No doubt the world is becoming keenly interested in the global cannabis industry, and much of that enthusiasm and attention is turning towards Canadian companies who are at the forefront of innovating and leading this sector,” said Zohar Krivorot, President and CEO of Cannara Biotech. “For Cannara Biotech, whose vision is to be a premium global cannabis company, this international listing will enable us to broaden our shareholder base, while allowing international investors to participate in our growth.”
The Canadian cannabis market is forecasted at $5.2B in year one of legalization and is expected growth of 20% annually to reach $10.8B in five years.
About Cannara Biotech Inc.
Cannara Biotech is building one of the largest indoor cannabis cultivation facility (625,000 square foot) in Canada and the largest in Quebec. Leveraging Quebec’s low electricity costs, Cannara Biotech’s facility will produce high-grade indoor cannabis and cannabis-infused products for the Canadian and international markets. Most recently, the Company entered the U.S. CBD-hemp market with an online eCommerce platform called shopCBD.com, which will also make the Company an aggregator of U.S. CBD-hemp products. For more information, visit our website: www.cannara.ca
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/cannara-biotech-shares-to-begin-trading-on-the-frankfurt-exchange-300792906.html
SOURCE Cannara Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2019/11/c8723.html
Contact:
Sabrina Williams, Communications Manager, sabrina.williams@cannara.ca, T: 514-543-4200 ext. 265; Zohar Krivorot, President & CEO, zohar@cannara.ca; Lennie Ryer CPA, CA, CFE, Chief Financial Officer, lennie@cannara.ca
- Published in Cannabis, Cannara, Marijuana, Medical Marijuana
CROP’s Washington Tenant Farm ‘Test Success’ With Nine Strains now Approved for Sale
Momentum Public Relations
Press Release: February 07, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today its Washington State tenant’s first crops have had successful test results.
The samples showed a range of Tetrahydrocannabolic Acid (‘THCA’) results and passed all tests for microbial impurities and no detectable pesticides. THCA is not directly used, but its presence is commonly analyzed when cannabis, or hemp-based products, are screened for THC. The tenant is now approved to begin selling the products in the Washington State market.
STRAIN |
THCA |
9 LB Hammer |
26.65% |
Woo |
19.47% |
Dutch Hawaiian |
22.54% |
Bubba Kush |
27.35% |
Gorilla Glue |
18.16% |
Green Crack |
17% |
Star Killer |
26.99% |
Ghost Train |
16.02% |
Dutch Treat (Distillate) |
79.1% THC 12.31% CBD |
The tenant is working with both bulk extraction buyers as well as retail locations under the Hempire and Evolution brands in the Washington market.
CROP CEO, Michael Yorke, stated: “This is an excellent result and certainly bodes well for the future. CROP’s tenant production teams continue to show what meticulous controls, defined production protocols and a focus on organic operations can mean in terms of resulting products.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: +1(604) 484-4206
View original content:http://www.prnewswire.com/news-releases/crops-washington-tenant-farm-test-success-with-nine-strains-now-approved-for-sale-300791442.html
- Published in Business, CROP Infrastructure, hemp, Marijuana, News Home
Bluestone Announces Additional Drill Results – 3.3 meters of 27.9 g/t Au and 260 g/t Ag at Cerro Blanco
Momentum Public Relations
Press Release: February 07, 2019
Bluestone Resources Inc. (TSXV: BSR) (OTCQB: BBSRF) (“Bluestone” or the “Company”) is pleased to announce additional infill drill results from resource conversion drilling underway at its high-grade Cerro Blanco Gold project. The focus of the ongoing infill drill program is to upgrade the Inferred Resources into Measured and Indicated Resources.
Bluestone recently announced results of a Feasibility Study on the high-grade Cerro Blanco Gold project (see press release January 29, 2019) where one of the principal recommendations for optimizing and further enhancing the project was through potential conversion of a portion of the 360,000 ounces of Inferred Resources to Measured and Indicated Resources through infill drilling (currently ongoing), which will be followed by an updated mineral resource and mine plan.
Two LM-75 diamond drill rigs are currently situated within the North Zone of the Cerro Blanco underground workings and are targeting specific veins in the upper part of the Cerro Blanco resource that can be converted to the Indicated Resource category by infill drilling.
The primary focus of the program is to upgrade the Inferred Resources identified during the previous infill drill program completed in 2018. In addition, this program is also designed to define new resources along known veins in the mine plan that extend outside of the current resource envelope.
Table 1. Significant Intercepts
HOLE ID | FROM (meters) |
TO (meters) |
CORE INTERVAL |
TRUE WIDTH |
Au g/t | Ag g/t | VEIN ID |
UGCB18-107 | Results Pending | ||||||
UGCB18-108 | Results Pending | ||||||
UGCB18-109 | 33.7 | 34.7 | 1.0 | 1.0 | 8.5 | P | New |
80.2 | 81.38 | 1.2 | 1.2 | 5.1 | 83 | VN_01 | |
86.0 | 87.1 | 1.1 | 1.1 | 4.8 | 44 | – | |
95.85 | 99.1 | 3.3 | 3.3 | 27.9 | 260 | VN_02 | |
UGCB18-110 | 33.7 | 34.74 | 1.0 | 1.0 | 19.9 | 170 | New |
108.4 | 110.4 | 2.0 | 2.0 | 10.0 | 113 | VN_02 | |
113.1 | 114.1 | 1.0 | 1.0 | 18.3 | 97 | VN_03 |
Notes: Intervals in bold are cited in the text of the news release. A complete table with hole coordinates and azimuth/dip information accompany the plan view attached to this release. P – Results pending
David Cass, Vice President of Exploration commented, “The infill drilling program has been designed to strategically target key veins with upgrading resource categories. To date, the program has had an excellent success rate with every key intercept expected to have a positive impact on future project economics, with intercepted veins showing remarkable consistency and continuity, validated by optimum hole orientations reflected in the drilled true widths.”
Hole UGCB18-109 and UGCB18-110 were both drilled from the same underground platform at a positive angle (+35 and +51 degrees respectively). The principal objective of these holes was conversion or extension of veins VN_01, 02 and 03 from Inferred to Indicated Resources. UGCB18-109 intercepted all targeted veins as planned with VN_02 assaying 3.3 meters at 27.9 g/t. Hole UGCB18-110 intersected veins VN_02 and VN_03 with the former assaying 2.0 meters at 10 g/t Au (see table).
Additionally, a new vein, located in the footwall of vein VN_01 was intercepted at 33.7 meters in both holes ( 1.0 meter at 8.5 g/t Au and 1.0 meter at 19.9 g/t Au) and correlates with intercepts drilled in holes UGCB18-101 and UGCB18-106 that assayed 1.95 meters at 12.6 g/t Au and 1.0 meter at 12.4 g/t Au respectively (see press releases January 9th and January 24th, 2019). This new vein is outside of the current resource and will be referred to as VN_18 in future updated resource models.
Drilling is continuing and further results will be reported as received. A plan view showing drill hole locations can be accessed by clicking HERE.
Quality Analysis and Quality Control
Assay results listed within this release were performed by Inspectorate Laboratories (“Inspectorate”), a division of Bureau Veritas, which are ISO 17025 accredited laboratories. Logging and sampling are undertaken on site at Cerro Blanco by Company personnel under a QA/QC protocol developed by Bluestone. Samples are transported in security-sealed bags to Inspectorate, Guatemala City, Guatemala, for sample preparation. Sample pulps are shipped to Inspectorate Laboratories in Vancouver, BC, Canada or Reno, NV, USA, and assayed using industry-standard assay techniques for gold and silver. Gold and silver were analyzed by a 30-gram charge with atomic absorption and/or gravimetric finish for values exceeding 5 g/t Au and 100 g/t Ag. Analytical accuracy and precision are monitored by the analysis of reagent blanks, reference material, and replicate samples. Quality control is further assured by Bluestone’s QA/QC program, which involves the insertion of blind certified reference materials (standards) and field duplicates into the sample stream to independently assess analytical precision and accuracy of each batch of samples as they are received from the laboratory. A selection of samples is submitted to ALS Chemex Laboratories in Vancouver for check analysis and additional quality control.
Qualified Person
David Cass, P.Geo., Vice President Exploration, is the designated Qualified Person for this news release within the meaning of National Instrument 43-101 and has reviewed and verified that the technical information set out above in this news release is accurate and therefore approves this written disclosure of the technical information.
About Bluestone Resources
Bluestone Resources is a mineral exploration and development company that is focused on advancing its 100%-owned Cerro Blanco Gold and Mita Geothermal projects located in Guatemala. A Feasibility Study on Cerro Blanco returned robust economics with a quick pay back. The average annual production is projected to be 146,000 ounces per year over the first three years of production with all-in sustaining costs of $579/oz (as defined per World Gold Council guidelines, less corporate general and administration costs). The Company trades under the symbol “BSR” on the TSX Venture Exchange and “BBSRF” on the OTCQB.
On Behalf of Bluestone Resources Inc.
“Darren Klinck”
Darren Klinck | President, Chief Executive Officer & Director
For further information, please contact:
Bluestone Resources Inc.
Stephen Williams | VP Corporate Development & Investor Relations
Phone: +1 604 646 4534
info@bluestoneresources.ca
www.bluestoneresources.ca
- Published in Bluestone Resources, Mining, News Home
Cannara Biotech Enters Cannabinoid-Infused Beverage Product Category
Momentum Public Relations
Press Release: February 7, 2019
Cannara Biotech Inc. (“Cannara Biotech” or the “Company”) (CSE: LOVE), a Montreal-based company that is building a vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced it has entered into a letter of intent with a leading Quebec microbrewery to develop cannabinoid-infused beverages. Following the regulations relating to edibles and beverages coming into effect next October, consumers will be able to purchase a variety of cannabinoid-infused beverages including non-alcoholic beer, kombucha and cider.
“Many of the world’s most successful beverage companies have aggressively invested in Cannabinoid-infused product development underscoring this product category’s market potential,” said Zohar Krivorot, President and CEO of Cannara Biotech. “This agreement also underscores our commitment in building Cannara Biotech into a premium Canadian cannabis company by leveraging our facility’s unique size and flexibility, partnering with industry leaders and supporting these joint ventures with both financial and human capital.”
Cannabinoid-infused beverage sales are forecasted to reach $260 million for North America by 2022, according to Canaccord Genuity. In addition to non-alcoholic cannabinoid-infused beer, this is the first of many partnerships that we intend to use the facility to execute our collaboration strategy to produce edibles, pet-products, cosmetics and other beverages for the Canadian market.
About Cannara Biotech Inc.
Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility located in Farnham, less than 45 minutes from Montreal. Leveraging Quebec’s low electricity costs, Cannara’s facility will produce high-grade indoor hydroponically grown cannabis and derivative products for the Canadian and international markets. Working with partners, Cannara will generate licensing revenues, rental revenues and revenue streams from joint-venture arrangements leveraging this valuable property. For more information, visit our website: www.cannara.ca
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/cannara-biotech-enters-cannabinoid-infused-beverage-product-category-300791611.html
SOURCE Cannara Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2019/07/c2566.html
Contact:
Sabrina Williams, Communications Manager, sabrina.williams@cannara.ca, T: 514-543-4200 ext. 265; Zohar Krivorot, President & CEO, zohar@cannara.ca; Lennie Ryer CPA, CA, CFE, Chief Financial Officer, lennie@cannara.ca
- Published in Cannabis, Cannara, Marijuana, Medical Marijuana
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Momentum Public Relations
Press Release: February 06, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market1.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1 |
Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html |
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/06/c8940.html
Contact:
regarding this press release, please contact: Christopher Hopton, CFO, Sirona Biochem Corp., Phone: 1.604.282.6064, Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
Momentum Public Relations
Press Release: February 05, 2019
Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients. This suspension does not affect the timing of the European application nor the development of the second-generation inhalation products.
Quality standards and process validations are imposed by pharmaceutical Good Manufacturing Practices (GMP). Just like our food chain, botanical drugs have unique challenges because of the potential for microbial contamination known as mycotoxins. Tetra’s investigational drug is composed of raw cannabis materials. In late spring 2018, Tetra initiated a study to monitor the microbial flora in its investigational product in order to validate the storage and drying process used in the fabrication of its investigational product. On December 20th the results of this ongoing study revealed the presence of the 3 mycotoxins in the lot of the investigational drug used for the clinical trials. Tetra communicated these findings within 24-hours of discovery to regulators and acted rapidly to ensure the safety and wellness of patients. As per discussions with Health Canada and the Ethics Review Board, Tetra contacted every patient involved in the ongoing clinical trials to suspend treatment and retrieve the investigational drugs.
Cannabis products that are ultimately sold in the recreational or medical market in Canada, are cultivated, processed and sold under the Cannabis Act, which are subject to Good Production Practices. Under the Good Production Practices, there is only a requirement to test for certain mycotoxins, namely aflatoxin and total content of mycotoxins. The cannabis raw materials purchased by Tetra for use in its investigational drug met the requirements under the Cannabis Act and Good Production Practices and tested below allowable limits.
However, Tetra is administering cannabis to patients as a drug for use in clinical trials which is governed by the requirements of the Food and Drugs Act and related Regulations. The fabrication, processing, packaging and sale of the investigational drug, must be conducted in accordance with the Good Manufacturing Practices (“GMPs”). Such GMPs require the validation of the storage and drying process to ensure the cannabis drug conforms to the quality standard of a prescription drug. Tetra, having acted in accordance with the requirements of the Food and Drugs Act and GMPs, detected the presence of mycotoxins other than aflatoxin in the experimental lot used for the validation. This led to the analyses of every lot being used in its clinical trials to verify for the presence of two other types of mycotoxins (Ochratoxin A, and DON (Deoxynivalenol; Vomitoxin) and the inclusion of this testing into the product specifications.
Tetra Bio-Pharma considers patient health and well-being to be non-negotiable. Tetra will take the next 6 months to assess the situation and propose a robust quality program to Health Canada so that Canadian patients taking its PPP001 prescription cannabis-derived drug are confident in the products’ quality and safety.
Tetra Bio-Pharma CEO and CSO Guy Chamberland holds a Ph.D. in Biomedical Sciences (toxicology) among other academic designations and is a well-respected expert in the field particularly in drug safety stated, “This unexpected development will result in a 6-month delay in the submission of the Canadian New Drug Submission or Drug Identification Number (DIN) application for PPP001. Tetra strongly believes that this delay will lead to a safer and higher quality drug for patients with advanced cancer. Through our research and development efforts, Tetra’s intention is to create higher quality for all cannabis-derived medicinal products. This is Tetra’s commitment to patient safety. We will continue to provide reports to Health Canada so that the Canadian government receives Tetra’s data in a timely manner so that regulators can ensure the safety and wellness of all Canadians consuming recreational and medical cannabis.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma